Hope for kids with rare brain cancer: new drug combo trial launches
NCT ID NCT07447076
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, gemcitabine and paxalisib, in children, teens, and young adults whose atypical teratoid rhabdoid tumor (ATRT) has come back or gotten worse. The goal is to find a safe dose and see if the drugs can control the tumor. About 29 participants will receive the drugs and undergo regular scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine and paxalisib
What this could lead to
If this works, it could offer a new treatment option to control recurrent ATRT brain tumors in children and young adults.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. The drug combo may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ATYPICAL TERATOID/RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact